Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 02, 2020 16:05 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics to Participate in September Investment Conferences

AUSTIN, Texas, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as...
August 18, 2020 16:05 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics to Present at World Orphan Drug Congress USA 2020

AUSTIN, Texas, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as...
August 10, 2020 08:30 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics Reports Second Quarter 2020 Financial Results and Corporate Highlights

Pegzilarginase Showed Durable Clinical Response and Sustained Reduction in Plasma Arginine at 56 Week Analysis of Phase 1/2 Open-Label Extension Study Initiated Phase 1/2 Clinical Trial of ACN00177...
June 01, 2020 16:05 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics to Present at BIO Digital 2020

AUSTIN, Texas, June 01, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as...
May 28, 2020 16:10 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics Announces Change of Location of Annual Meeting of Stockholders to Be Held June 8, 2020

AUSTIN, Tx., May 28, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as...
May 26, 2020 08:30 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology

Pegzilarginase Showed Durable Clinical Response at 56 Week Analysis All Patients Demonstrated a Marked and Sustained Reduction in Plasma Arginine Favorable Safety Profile, Consistent with...
May 19, 2020 08:30 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics to Present Late-Breaking 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology

AUSTIN, Texas, May 19, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as...
May 07, 2020 08:30 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics Reports First Quarter 2020 Financial Results and Corporate Highlights

Gross Proceeds of $138 Million from April 2020 Public Offering Extends Cash Runway Through 2022 Clinical Trial Application for ACN00177 Approved by MHRA; Progress Toward Phase 1/2 Clinical Trial in...
April 30, 2020 16:05 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

AUSTIN, Texas, April 30, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions...
April 28, 2020 09:07 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics Announces Pricing of $120 Million Public Offering

AUSTIN, Texas, April 28, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as...

Next Page keyboard_arrow_right